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2Abstract:41
A modified tri-axial electrospinning process was developed for the generation of a42
new type of pH-sensitive polymer/lipid nanocomposite. The systems produced are43
able to promote both dissolution and permeation of a model poorly water-soluble drug.44
First, we show that it is possible to run a tri-axial procress with only one of the three45
fluids being electrospinnable. Using an electrospinnable middle fluid of Eudragit46
S100 (ES100) with pure ethanol as the outer solvent and an unspinnable47
lecithin-diclofenac sodium (PL-DS) core solution, nanofibers with linear morphology48
and clear core/shell structures can be fabricated continuously and smoothly. X-ray49
diffraction proved that these nanofibers are structural nanocomposites with the drug50
present in an amorphous state. In vitro dissolution tests demonstrated that the51
formulations could preclude release in acidic conditions, and that the drug was52
released from the fibers in two successive steps at neutral pH. The first step is the53
dissolution of the shell ES100 and the conversion of the core PL-DS into sub-micron54
sized particles. This frees some DS into solution, and later the remaining DS is55
gradually released from the PL-DS particles through diffusion. Ex vivo permeation56
results showed that the composite nanofibers give a more than two-fold uplift in the57
amount of DS passing through the colonic membrane as compared to pure DS; 74%58
of the transmitted drug was in the form of PL-DS particles. The new tri-axial59
electrospinning process developed in this work provides a platform to fabricate60
structural nanomaterials, and the core-shell polymer-PL nanocomposites we have61
produced have significant potential applications for oral colon-targeted drug delivery.62
Keywords: Tri-axial electrospinning; core-sheath fibers; polymer-lipid63
nanocomposites; colon-targeted drug delivery; electrospinnability64
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31. Introduction70
The fabrication of advanced drug delivery systems (DDSs) is increasingly71
dependent on the creation of complex architectures and understanding72
structure-activity relationships at the nanoscale [1-3]. To this end, core-shell73
nanostructures have been very widely studied in the production of functional74
nanomaterials, including those for biomedical applications [4-6]. For drug delivery75
and controlled release, both the core and shell can be loaded with an active76
pharmaceutical ingredient (API) and/or with different types of pharmaceutical77
excipients. Applications of such systems include improving the solubility of poorly78
water-soluble drugs, controlled release of multiple APIs from a single dosage form, or79
tunable multiple phase release [7-9].80
Over recent years, polymers and lipids have been the most widely used81
pharmaceutical excipients, and these materials have acted as the basis for a broad82
gamut of novel DDSs, being exploited to alter the biopharmaceutical and83
pharmacokinetic properties of the drug molecule for favorable clinical outcomes84
[3,10,11]. Numerous core-shell polymeric nanoparticles (NPs) and lipid-based DDS85
(such as solid lipid dispersions and liposomes) have been investigated for drug86
delivery through varied administration routes [12-15]. Novel strategies derived from87
the combined usage of polymers and phospholipids (PLs) have been reported for88
some biomedical applications (including controlled release) and are presently of89
intense interest in the pharmaceutics field. However, virtually all the reported90
polymer-lipid composites are in the form of microparticles or NPs [4,8,16-18].91
4Core-shell nanofiber-based DDS have received relatively little attention, and to the92
best of our knowledge there are no reports of drug-loaded polymer-lipid nanofibers93
being used in drug delivery.94
Electrospun nanofibers, comprising an API loaded into a filament-forming95
polymer, have been the focus of much research. They are prepared from a96
co-dissolving solution of a drug and polymer; this is ejected from a syringe with97
electrical energy used to rapidly evaporate the solvent and yield one-dimensional98
fibers with diameters frequently on the nanoscale. This technique is scalable, and99
several recent reports address large scale fabrication and the potential for commercial100
products [19-22]. The intense research effort invested in these materials thus appears101
to be about to yield products which can make a major difference to patients’ lives.102
Electrospinning is a facile, one-step procedure, and the products form as a visible and103
flexible mat which can easily be recovered from the collector without significant loss104
of material or damage. The nanofibers produced can further be used as templates to105
manipulate molecular self-assembly to create drug-loaded NPs or liposomes; the106
electrospinning technique thus provides not only a bridge between fiber-based and107
NP-based DDSs, but also between solid and liquid dosage forms [23-26].108
The most simple, single-fluid, electrospinning process has been explored for109
approaching two decades, and the applications of the resultant monolithic nanofibers110
have been probed in a wide range of fields. Current developments in electrospinning111
are focused in two key areas. The first is the manufacture of electrospun nanofibers on112
an industrial scale [27-29]. The second line of research involves developing advanced113
5electrospinning techniques to yield nanofibers with sophisticated structural114
characteristics (such as multiple-compartment nanofibers, core-shell nanofibers, or115
structured fibers with varied distributions of the API), which in turn impart tunable116
and multiple functionalities [30-32]. Because of the popularity of core-shell117
nanostructures and the relative ease of the process, coaxial electrospinning (in which118
two needles, one nested inside another, are used to handle two working fluids) has119
been the focus of much research. Other advanced approaches such as side-by-side120
electrospinning (to yield Janus fibers), tri-axial electrospinning (giving three-layer121
composites), and other types of multiple-fluid electrospinning have been neglected in122
comparison [6,9,33].123
Compared with single-fluid electrospinning, the standard coaxial experiment has124
greatly expanded the range of fibers which can be produced. These include not only125
core-shell fibers [34,35], but also fibers prepared from materials without126
filament-forming properties [36] and used as templates for creating nanotubes (from127
the fiber as a whole) or the “bottom-up” generation of NPs (self-assembled from the128
components loaded in the fibers) [26, 37]. For biomedical applications, core-shell129
nanofibers proffer a series of new possibilities; for instance, it is possible to protect a130
fragile active ingredient such as a protein from the stresses of the electrospinning131
processes by confining it to the core, or to vary the APIs concentration in the core and132
shell to achieve complex drug release profiles [38-41]. In the traditional coaxial133
process the sheath working fluid must be electrospinnable, but a modified process in134
which one can utilize unspinnable liquids as the sheath fluid is also possible. The135
6number of polymers which can be directly electrospun is rather limited, but there are136
numerous unspinnable liquids, and the modified coaxial process should hence further137
expand the range of functional nanofibers which can be produced [38,42,43].138
The above discussion is focused on the simultaneous processing of two fluids;139
working with three or even four fluids simultaneously is also possible, however140
[44-49]. For example, Han and Steckl reported tri-layer nanofibers for biphasic141
controlled release, using dyes as model active ingredients [49]. In very recent work,142
we successfully developed a tri-axial electrospinning process to generate nanofibers143
with a gradient distribution of the API, allowing us to achieve zero-order drug release144
profiles [31]. However, in all the tri-axial electrospinning processes reported to date,145
the three working fluids are all electrospinnable. This limits the applications of the146
process. If unspinnable liquids can be processed in combination with spinnable147
working solutions, a much broader selection of functional products could be designed148
and generated.149
Building on our previous work developing modified coaxial [38,42,43] and150
standard tri-axial electrospinning [50], here we report the first modified tri-axial151
electrospinning process. We have used this process to create core-shell fibers152
comprising a lipid-drug core and a pH sensitive shell, thereby allowing us to153
demonstrate that only an electrospinnable central fluid is required to achieve a154
successful tri-axial process. The polymer-lipid nanocomposites produced showed155
desirable functional performance in altering the release behavior of the model drug156
diclofenac sodium and improving its permeation through the colonic membrane.157
72 Experimental158
2.1. Materials159
Eudragit S100 (ES100, Mw=135,000), a methacrylic acid/methyl methacrylate160
copolymer which only dissolves at pH > 7.0, was obtained from Röhm GmbH161
(Darmstadt, Germany). Diclofenac sodium (DS, a non-steroidal anti-inflammatory162
drug with potent anti-inflammatory, analgesic and antipyretic properties) was163
purchased from the Hubei Biocause Pharmaceutical Co., Ltd. (Hubei, China).164
Lecithin (PL, extracted from egg yolk, and containing lysophosphatidylcholine,165
sphingomyelin, and neutral lipids in minor quantities), N,N-dimethylacetamide166
(DMAc), anhydrous ethanol, methylene blue and basic fuchsin were purchased from167
the Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). All other chemicals168
used were analytical grade, and water was doubly distilled before use.169
2.2. Electrospinning170
The tri-layer concentric spinneret was homemade. Three syringe pumps171
(KDS100, Cole-Parmer, Vernon Hills, IL, USA) and a high-voltage power supply172
(ZGF 60kV/2 mA, Shanghai Sute Corp., Shanghai, China) were used for173
electrospinning. The collector comprised a flat piece of cardboard wrapped with174
aluminum foil. All electrospinning processes were carried out under ambient175
conditions (21 ± 5 °C with a relative humidity of 47 ± 5 %). Experiments were176
recorded using a digital camera (PowerShot A490, Canon, Tokyo, Japan). The177
spinneret to collector distance was fixed at 15 cm for all experiments.178
The outer fluid was pure anhydrous ethanol. The middle fluid consisted of 14.0 g179
8ES100 in 100 mL of a mixture of ethanol / DMAc (90:10 v/v). The inner fluid was180
prepared from 3 g PL and 0.6 g DS in 10 mL ethanol. After initial optimization181
experiments, the applied voltage was fixed at 15 kV. To facilitate observation of the182
electrospinning processes, 10 mg/L methylene blue was added to the inner fluid and 5183
mg/L basic fuchsin to the middle fluid. Four different sets of fibers were prepared184
with varied flow rates, as detailed in Table 1.185
186
Table 1. Key details of the electrospinning processes and resultant fibers187
188
189
190
191
192
193
194
195
196
2.3. Characterization197
2.3.1. Morphology198
The morphology of the fibers was determined using a Quanta FEG450 field199
emission scanning electron microscope (FESEM; FEI Corporation, Hillsboro, OR,200
USA). Prior to examination, samples were gold sputter-coated under a nitrogen201
atmosphere to render them electrically conductive. Images were recorded at an202
excitation voltage of 20 kV. The average fiber size was determined by measuring their203
diameters at more than 100 places in FESEM images, using the NIH Image J software204
(National Institutes of Health, MD, USA). To view the cross-sections of sample F2, a205
section of the fiber mat was placed into liquid nitrogen and manually broken before206
No. Process
FOa
(mL/h)
FMa
(mL/h)
FIa
(mL/h)
Morphologyb Diameter (μm) 
F1 Single 0 3.0 0 Linear 1.27± 0.13
F2
Tri-axial
0.5 2.0 0.5 LInear 0.55±0.06
F3
0.5
1.6 0.9
Linear, with some
beads
0.47±0.05
F4 1.0 1.6 0.4 Spindles-on-a-string ----
9gold coating.207
Transmission electron microscope (TEM) images of the samples were recorded208
on a JEM 2100F ﬁeld emission TEM (JEOL, Tokyo, Japan). Samples were collected 209
by fixing a lacey carbon-coated copper grid on the collector and electrospinning210
directly onto it for several minutes.211
2.3.2. Physical form and compatibility212
X-ray diffraction (XRD) was conducted using a D/Max-BR diffractometer213
(Rigaku, Tokyo, Japan) with Cu Kα radiation over the 2θ range 5 to 60° at 40 kV and214
30 mA. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR)215
spectroscopy was carried out on a Nicolet-Nexus 670 FTIR spectrometer (Nicolet216
Instrument Corporation, Madison, USA) from 500 cm–1 to 4000 cm–1 at a resolution217
of 2 cm−1.218
2.3.3. In vitro dissolution tests219
To determine drug loading efficiency (LE), 0.100 g of the fibers was added into220
10 mL of a 10% v/v ethanol solution in water, in order to extract all the loaded DS.221
The resultant solutions were diluted using phosphate buffered saline (PBS, pH7.0,222
0.1M) to a suitable concentration for UV measurement. The LE was calculated using223
the following equation:224
LE(%) = (DS mass measured)/(theoretical DS mass in the formulation)×100%225
In vitro dissolution tests were carried out according to the Chinese226
Pharmacopoeia (2015 Ed.). Method II, which is a paddle method, was undertaken227
using a RCZ-8A dissolution apparatus (Tianjin University Radio Factory, Tianjin,228
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China). 280 mg of fibers F2 or 20 mg of the DS raw material (particle size <30 μm)229
were first placed in 600 mL of 0.1 M HCl. Two hours later, 2.4 g NaOH was added to230
neutralize the dissolution media. The temperature of the dissolution medium was 37 ±231
1 °C and the instrument was stirred at 50 rpm. Sink conditions were maintained, with232
C < 0.2Cs. At predetermined time points, 5.0 mL aliquots were withdrawn from the233
dissolution medium and replaced with distilled water to maintain a constant volume.234
After filtration through a 0.22 µm membrane (Millipore, Billerica, MA, USA) and235
appropriate dilution with PBS, samples were analyzed at λmax = 276 nm using a236
UV–vis spectrophotometer (UV-2102PL, Unico Instrument Co. Ltd., Shanghai,237
China). The cumulative amount of DS released at each time point was back-calculated238
from the data obtained against a predetermined calibration curve. Experiments were239
performed seven times, and the average results from six of these replicates are240
reported as mean ± S.D.241
During the in vitro dissolution process, dissolution media from the seventh242
replicate was withdrawn and the transmittance at λ=500 nm measured using the 243
UV–vis spectrophotometer. The average hydrodynamic diameter and size distribution244
of the particles in the final dissolution medium from these experiments were245
determined using a BI-200SM static and dynamic light scattering (SDLC) instrument246
(Brookhaven Instruments Corporation, Austin, TX, USA).247
2.3.4. Ex vivo permeation tests248
Ex vivo permeation studies were performed using a RYJ-6A diffusion test249
apparatus (Shanghai Huanghai Drug Control Instrument Co., Ltd., Shanghai, China),250
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in which materials were mounted in six Keshary-Chien glass diffusion cells and a251
water bath system maintained a constant temperature of 37 ± 0.2 °C. Each cell had a252
diffusion area of 2.60 cm2, and the receptor compartment had a capacity of 7.2 mL253
PBS (pH7.0, 0.1M). Each donor compartment was filled with 1.0 mL PBS and the254
hydrodynamics in the receptor compartment were maintained by stirring at 50 rpm255
with a Teflon coated magnetic bead. Large intestines were obtained from pigs after256
slaughtering (Baoshan Jiangwan slaughterhouse, Shanghai, China). The intestine was257
washed carefully with physiological saline solution (NaCl 0.9% w/v) to remove258
non-digested food. The colonic membranes were peeled away from the intestines and259
fixed on diffusion cells with the mucosal walls upward. They were equilibrated at260
35 °C for 30 min before permeation tests.261
The F2 fibers (140 mg) were placed on the mucosal surface in the chambers.262
Samples (1 mL) were withdrawn from the receptor compartment at timed intervals263
and 1 mL fresh PBS was added to maintain the volume of fluid here at a constant264
level. The aliquots were filtered through a 0.22 μm membrane (Millipore, Billerica, 265
MA, USA). The absorption of the filtrate was measured at 276 nm to determine the266
amount of DS present in the aqueous phase. The semi-solid residue was dissolved267
using 10 mL of a 10% v/v ethanol solution in water and diluted with PBS before268
measuring absorbance, in order to determine its DS content of. All measurements269
were carried out in triplicate. Permeation experiments with 10 mg of pure DS (particle270
size <30 μm) as a control were also carried out.271
2.4. Statistical analysis272
The experimental data are presented as mean ± SD. The results from the in vitro273
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dissolution tests and ex vivo permeation tests were analyzed using one-way ANOVA.274
The threshold significance level was set at 0.05. Thus, p (probability) values lower275
than 0.05 were considered statistically significant.276
3. Results and discussion277
3.1. Implementation of modified tri-axial electrospinning278
A diagram illustrating the modified tri-axial electrospinning process is shown in279
Fig. 1. The system consists of four components: three syringe pumps to drive the280
working fluids, a power supply, a fiber collector, and a three layer concentric281
spinneret. In modified coaxial electrospinning, the use of a spinnable core solution282
can ensure a successful process regardless of the electrospinnability of the sheath fluid283
[43]. Here, the central solution is electrospinnable, and this is utilized to achieve284
tri-axial electrospinning even though the outer fluid is pure solvent and the inner fluid285
is unspinnable.286
287
288
289
290
291
292
293
294
295
296
297
Fig. 1 A diagram of the modified tri-axial electrospinning process and its use for298
preparing core-shell drug-loaded nanofibers.299
The homemade tri-concentric spinneret and its connection with the power supply300
and three working fluids are shown in Fig. 2a. An alligator clip was used to connect301
the power supply to the spinneret, which was directly fixed to the syringe holding the302
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outer fluid. The middle and inner fluids were connected to the spinneret through303
high-elastic silicon tubing.304
The design of the spinneret is of critical importance in ensuring a robust and305
reproducible electrospinning process [42,48]. A well-designed spinneret must provide306
a suitable template for producing the desired nanofiber architectures, and must be307
developed bearing in mind the behavior of the working fluids under an electrical field.308
The spinneret used in this work is exhibited in the top-right and bottom-right insets of309
Fig. 2a. It consists of three concentric capillaries composed of austentic stainless steel310
(O6Cr19Ni10, GB24511 in China). The inner, middle and outer capillaries have outer311
diameters of 0.4, 1.6, 2.8 mm and inner diameters (Di) of 0.20, 1.3 and 2.2 mm,312
respectively. The end of the inner capillary projects 0.2 mm out of the central one,313
which similarly projects 0.2 mm from the outer capillary. This design helps to ensure314
the encapsulation of the inner fluid by the middle fluid, and in turn the middle by the315
outer fluid. This structure should also help to prevent mixing of the working fluids316
when they are ejected from the spinneret.317
318
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323
324
325
Fig, 2. The implementation of modified tri-axial electrospinning: (a) the connection of326
the spinneret with the power supply and the working fluids (left), and images of the327
tri-concentric spinneret (insets); (b) a digital photograph of the tri-axial process (left),328
the tri-layer droplet before a voltage of 15 kV was applied (top-right) and the329
compound Taylor cone (bottom-right).330
331
Under optimised conditions (see Section 2.2), successful electrospinning could332
be achieved as shown in Fig. 2b. The process involves three steps including Taylor333
cone formation, the emission of a straight fluid jet and then an unstable region with334
gradually enlarged bending and whipping loops. The top-right inset of Fig. 2b335
displays the droplets ejected from the spinneret with no voltage applied. Both the blue336
inner fluid and pink middle fluids were observed to diffuse into the outer fluid to337
some extent, as demonstrated by their gradually increased sizes and decreased size of338
the outer (colourless) solvent moving away from the spinneret. However, the three339
working fluids form a clear three-layer compound Taylor cone when a voltage of 15340
kV was applied, as shown in the bottom-right inset of Fig. 2b.341
The modified tri-axial electrospinning process can be run continuously and342
smoothly, without any clogging or other adverse phenomena arising. These are343
frequently encountered in traditional single-fluid and coaxial electrospinning [50], but344
spinning with a pure solvent as the exterior fluid has been shown to reduce incidents345
of clogging as well as to improve the uniformity of the fibers produced in the latter346
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process [42]. The use of pure solvent as the outer layer will: 1) lubricate the spinneret347
to retard clinging; 2) prevent the formation of semi-solid substance on the surface of348
the fluid jets; 3) protect the inner fluid from any environmental fluctuations; and, 4)349
lead to a longer drawing period under the electrical field, and thus to narrower fibers.350
3.2. Morphology and core-shell structures of the created nanofibers351
FESEM images of fibers F1 to F4 are shown in Fig. 3. When the inner and352
outer fluids were turned off, a traditional single-fluid electrospinning of the middle353
ES100 solution could be achieved. Although manual intervention was needed354
periodically to remove semi-solid substances which collected on the spinneret, the355
resultant ES100 fibers were linear without any beads-on-a-string or356
spindles-on-a-string morphology (Fig. 3a1 and 3a2). These fibers have an average357
diameter of 1.27 ± 0.13 µm, with an uneven and wrinkled surface (Table 1, Fig. 3a2).358
This is a result of barometric pressure, when residual solvent which was not359
evaporated during electrospinning escaped from the fibers. Single-fluid360
electrospinning easily traps solvent in the fibers because of the formation of a solid361
“skin” on the fluid jet during the solidification process.362
The F2 fibers are linear with an average diameter of 0.55 ± 0.06 µm and smooth363
surfaces (Fig. 3b1 and 3b2, Table 1). This can be attributed to the surrounding outer364
solvent and appropriate selection of the flow rates of the three working fluids (0.5, 2.0365
and 0.5 mL/h for outer, middle and inner fluids, respectively). If the flow rate of the366
outer solvent is kept constant and those of the middle and inner fluid altered to 1.6367
and 0.9 mL/h respectively, the resultant F3 material has many beads clinging to the368
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fibers, although the latter are still linear with an average size of 0.47 ± 0.05 µm (Fig.369
3b1 and 3b2, Table 1). It is thought that this high flow rate of the inner fluid causes it370
to penetrate the middle and outer fluids to form round PL-DS beads on the fiber371
surfaces.372
If the flow rate of the outer solvent is doubled to 1.0 mL/h, the fibers generated373
exhibit a typical spindles-on-a-string morphology (Fig. 3d1 and 3d2). Some374
unexpected clumps are also formed within the fiber mat, as shown in the inset of Fig.375
3d1. These are ascribed to PL escaping from the inner fluids. A further increase of the376
outer solvent flow rate was found to result in an electrospraying process. These results377
demonstrate that the selection of flow rates is a key parameter which must be378
controlled to ensure the formation of a core-shell nanostructure.379
380
381
382
383
384
385
386
387
388
Fig. 3. FESEM images of the core-shell nanofibers and their size distributions; (a1389
and a2) F1; (b1 and b2) F2; (c1 and c2) F3; (d1 and d2) F4, the inset shows a clump390
of PL-DS.391
392
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FESEM images of cross-sections of F2 (Fig. 4a) and TEM images (Fig. 4b)393
demonstrate that the fibers have clear core/shell structures. Both the FESEM and394
TEM images suggest that the PL-DS core has a diameter of approximately 300 nm.395
396
397
398
399
Fig. 4. (a) A FESEM and (b) TEM image of the cross-sections of F2.400
401
3.3. Physical form and component compatibility402
XRD data are depicted in Fig. 5; these clearly demonstrate that DS is crystalline,403
with many sharp Bragg reflections visible in its pattern. ES100 exhibits only a broad404
hump, characteristic of an amorphous material. PL exists as a paste at an ambient405
temperature of 21 °C, yet shows a sharp reflection at 2θ=5.18º. This suggests that 406
there are liquid crystals present in the PL paste, with an ordered lamellar structure as407
reported in the early literature [51]. All reflections from PL and DS are absent in the408
patterns of the core-shell F2 fibers, suggesting the formation of an amorphous PL-DS409
complex.410
411
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413
414
415
416
Fig. 5. XRD patterns of the raw materials (PL, EL100 and DS) and F2.417
418
419
The potential secondary interactions between the fiber components were420
investigated using ATR-FTIR, and the results are shown in Fig. 6. DS has three421
characteristic peaks at 1574, 1553 and 1507 cm-1 arising from its benzene rings. In the422
spectrum of PL, the CH2 symmetric and asymmetric vibrations at 2854 cm-1 and 2923423
cm-1 and the antisymmetric stretch of N+(CH3)3 at 968 cm-1 comprise the most424
prominent features. These peaks similarly appear in the spectrum of the fibers,425
confirming the presence of PL with ES100. However, the characteristic peaks from426
the benzene rings of DS cannot be seen in the F2 spectrum. This can be attributed to427
secondary interactions between PL and DS. Hydrophobic interactions, in addition to428
possible hydrogen bonding and electrostatic interactions, can arise between all three429
components in F2, as is clear from a consideration of the molecular structures in Fig.430
6. These secondary interactions should ensure that the drug and excipients are highly431
compatible, favorable for the stability of the core-shell nanocomposites.432
433
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436
437
438
Fig. 6. ATR-FTIR spectra and the molecular formulae of the fiber components.439
440
3.4. Functional performance441
DS has a maximum absorbance at 276 nm, which was used to construct a442
calibration curve: A=0.0085+0.0279 C (R=0.9997) within a linear range from 2 to 50443
µg/mL. The drug content in F2 was first assayed, and found to be 7.26 ± 0.31% (n =444
6), almost identical to the calculated value of 7.14%.445
The in vitro release profiles of F2 and the DS starting material are shown in Fig.446
7a. DS is virtually insoluble in acidic conditions, with a small increase in solubility447
when the pH is raised to neutral. After 2 h in acid, 2.8% of DS from the raw material448
was freed into the dissolution media. When the pH was raised to neutral, the DS449
particles gradually dissolved over ca. 3 hours. For F2, 2.1% of the loaded DS was450
released during the first 2 h. In the neutral dissolution media, the nanofibers released a451
total of 79.1% of the incorporated DS over 22 h.452
ES100 is a pH-sensitive polymer, and is insoluble at pHs below 7.0; it can thus453
be used to target DS to the colon region. DS is a popular API for oral administration454
and is frequently used in the treatment of pain and peri-operatively. However, it can455
easily result in an anaphylactic reaction, and to an allergic reaction in the digestive456
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tract [52,53]. With traditional electrospun nanofibers, the drug is released by diffusion457
through an insoluble polymeric matrix, or by an erosion mechanism from a458
water-soluble carrier (or a combination of both processes) [39,43]. Here the drug459
release from the core-shell composites is expected to include two successive steps460
(Fig. 7b). First, dissolution of the pH-sensitive ES100 shell will occur, with some461
diffusion of DS from the insoluble core PL. After dissolution of the shell ES100, the462
core PL-DS is not thought to be able to endure the shear forces of stirring applied463
during the experiment and thus we propose that the core is broken up into PL-DS464
particles. The DS is then gradually released from the resultant DS-PL aggregates.465
Thus in the dissolution tests, the released drug (%) corresponds to the DS molecules466
which are in solution (the DS-PL aggregates in suspension are removed by filtration).467
468
469
470
471
472
473
474
475
Fig. 7. In vitro dissolution of DS and D2 (a) and the proposed drug release476
mechanism (b).477
478
To further investigate the drug release mechanism and validate this hypothesis,479
the transmittance of the dissolution media and light scattering studies were performed.480
The changes in transmittance at λ=500 nm are shown in Fig. 8a. DS has no 481
absorbance above 320 nm, and thus any turbidity of the dissolution media recorded at482
this wavelength must result from the formation of a PL-DS suspension. In the first 2 h,483
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the transmittance remains virtually constant. After the pH is raised to neutral, the484
transmittance values decreased for 3 h, after which they level out at around 77%. This485
is consistent with the dissolution of the shell ES100 occurring over this period and486
resulting in PL-DS nanoparticles.487
The SDLC results obtained on the final dissolution medium are given in Fig. 8b.488
The PL-DS particles formed have an average diameter of 434 nm with a489
polydispersity index (PDI) of 0.187.490
491
492
Fig. 8. (a) The transmittance of the dissolution medium measured at 500 nm as a493
function of time and (b) the sizes of the PL-DS particles measured by SDLC at the494
end of the dissolution experiment.495
496
The results of permeation tests are presented in Fig. 9. DS is a Biopharmaceutical497
class II drug, meaning it is poorly water-soluble but is able to effectively cross fatty498
membranes [54]. After 12 h only 3.7 mg of the pure drug was transmitted into the499
receptor cells. The dissolution of DS is very slow because there is only a very limited500
amount of aqueous medium in the donor cell (cf. the dissolution experiments, which501
are performed under sink conditions) [55]. For the F2 fibers, both dissolved DS and502
the PL-DS particles penetrate the bio-membranes into the receptor cells [56].503
Although the core-shell nanofibers provided sustained release of DS in dissolution504
studies (much slower than the release from pure DS), after 12 h 8.1 ± 0.46 mg DS505
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from F2 had entered the receptor chamber. Of this amount, 1.7 ± 0.23 mg was present506
in the aqueous phase (or in particles below 220 nm in size, which could pass through507
the filters used). This suggests that (8.1-1.7)/8.1×100=79% of the DS penetrated508
through the mucosal membrane in the format of PL-DS particles. For oral509
administration applications, this drug delivery route should alleviate any potential510
allergic reactions with the digestive tracts.511
Many commercial tablets are essentially a physical mixture of drug powders and512
polymeric carrier, the latter being added to modulate the drug release behavior. The513
combined use of polymer and lipid in the fibers prepared in the work is able to both514
protect the API from release in the stomach and provide sustained release in the515
colonic region, and also ensure improved trans-membrane permeability, leading to516
more effective absorbance. This strategy is particularly useful for oral delivery of517
Class IV drugs (which are both poorly water-soluble and have poor permeation518
properties). Drug-loaded electrospun fibers can easily be converted into routine oral519
solid dosage forms such as tablets and capsules using traditional pharmaceutical520
protocols [57-59].521
522
Fig. 9. Ex vivo permeation profiles of the F2 fibers and pure DS (n=6).523
524
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3.5. Perspectives525
Coaxial electrospinning is often regarded as a major breakthrough in this field526
[60,61]. The fact that only one of the working fluids needs to be electrospinnable for a527
successful coaxial process significantly widens the range of materials which can be528
processed, and a very broad family of core-shell nanostructures can be produced.529
There are only about 100 polymers which can be directly electrospun into fibers, and530
often these can only be processed within a narrow window of conditions531
(concentration, voltage, etc). The introduction of unspinnable fluids in the modified532
coaxial processes greatly expands the capability of this simple technology to produce533
nanoscale products from a large range of raw materials. Furthermore, modified534
coaxial electrospinning permits all types of liquid phase (including solvents, small535
molecule solutions, dilute polymer solutions, suspensions and also emulsions) to be536
processed.537
In this work, we report the first example of modified tri-axial electrospinning.538
Similar to modified co-axial spinning, this moves technology beyond the traditional539
tri-axial process in which all three working fluids are required to be individually540
electrospinnable. In our work, two of the three fluids were unspinnable alone: an541
electrospinnable middle layer fluid is sufficient to ensure a successful tri-axial process.542
This proof-of-concept work indicates that there are many possibilities in developing543
functional nanofibers through the introduction of unspinnable outer-layer and544
inner-layer working fluids into tri-axial processes.545
The feasibility of the different tri-axial electrospinning processes which can be546
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conceived are summarized in Fig. 10. A process with three spinnable working fluids547
(Process I) has been reported in several publications [31,44,45]. Processes II, III and548
IV have two of the three fluids being electrospinnable, and these are feasible provided549
the working fluids are compatible. This report is an example of Process V, with a550
spinnable middle layer fluid used to support unspinnable outer and inner fluids. For551
processes VI and VII, the two unspinnable fluids are adjacent to each other. This may552
result in diffusion of the solutes and formation of a mixture of the two unspinnable553
liquids, and thus it is anticipated that such to tri-axial electrospinning processes will554
result in failure.555
556
557
558
559
560
561
562
563
564
565
566
Fig. 10. The feasibility of different tri-axial electrospinning processes.567
568
4. Conclusions569
A modified tri-axial electrospinning process was successfully implemented to create570
core-shell nanofibers, in which a spinnable Eudragit S100 (ES100) solution was used571
as the middle fluid to support the outer solvent and an unspinnable phosphatidyl572
choline (PL)/diclofenac sodium (DS) inner solution. This resulted in a continuous and573
trouble-free nanofabrication process. The resultant core-shell nanofibers have a linear574
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morphology with an obvious core-shell structure. XRD demonstrated that the575
nanofibers are structural nanocomposites with both the drug DS and also the lipid576
carrier PL losing their original crystalline physical forms and being transferred into an577
amorphous state. These core (PL-DS)-shell (ES100) nanostructures can protect the578
drug from release in acidic conditions to give colon-targeted release. They release the579
drug through two successive steps at neutral pH: first, dissolution of the shell ES100580
occurs, which is believed to generate PL-DS sub-micron sized particles. Subsequently,581
release of DS from the particles occurs. The composite nanofibers lead to more than582
twice as much drug permeation through the colonic bio-membrane when compared583
with pure DS. The tri-axial electrospinning process developed in this work should584
provide a new platform to fabricate structural nanomaterials, and polymer-PL585
nanocomposites such as those prepared here can be utilized for effective oral drug586
delivery.587
Acknowledgements588
This work was supported by the China NSFC/UK Royal Society cost share589
international exchanges scheme (No. 51411130128/IE131748), the National Science590
Foundation of China (Nos. 51373101 and 51373100), the Natural Science Foundation591
of Shanghai (No. 13ZR1428900) and the Hujiang Foundation of China (No. B14006).592
DP and LXK are also indebted to the Key Laboratory of Advanced Metal-based593
Electrical Power Materials, Shanghai Municipal Commission of Education.594
References595
[1] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano596
2009;3:16-20.597
26
[2] Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug598
delivery. Adv Drug Del Rev 2004;56:1621-1633.599
[3] Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering600
biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov601
2014;13:655-672.602
[4] Sun J, Zhang L, Wang J, Feng Q, Liu D, Yin Q, Xu D, Wei Y, Ding B, Shi X,603
Jiang X. Tunable rigidity of (polymeric core)–(lipid shell) nanoparticles for regulated604
cellular uptake. Adv Mater 2015; 27:1402-1407.605
[5] Liang X, Li J, Joo JB, Gutiérrez A, Tillekaratne A, Lee I, Yin Y, Zaera F.606
Diffusion through the shells of yolk–shell and core–shell nanostructures in the liquid607
phase. Angrew Chem Int Ed 2012;51:8034-8036.608
[6] Chen G, Xu Y, Yu DG, Zhang DF, Chatterton NP, White KN. Structure-tunable609
Janus fibers fabricated using spinnerets with varying port angles. Chem Commun610
2015;51:4623-3626.611
[7] Bikiaris DN. Solid dispersions, Part II: new strategies in manufacturing methods612
for dissolution rate enhancement of poorly water-soluble drugs. Exp Opin Drug Del613
2011; 8:1663-1680.614
[8] Eltayeb M, Stride E, Edirisinghe M. Electrosprayed core-shell polymer-lipid615
nanoparticles for active component delivery. Nanotechnology 2013;24:465604.616
[9] Yu DG, Wang X, Li XY, Chian W, Li Y, Liao YZ. Electrospun biphasic drug617
release polyvinylpyrrolidone/ ethyl cellulose core/sheath nanofibers, Acta Biomater618
2013;9:5665-5672.619
[10] Labbaf S, Deb S, Camma G, Stride E, Edirisinghe M. Preparation of620
multi-component drug delivery nanoparticles using a triple-needle621
electrohydrodynamic device. J Colloid Interf Sci 2013;409:245-254.622
[11] Hubbell JA, Chikoti A. Nanomaterials for drug delivery. Science623
2012;337:303-305.624
[12] Perez RA, Kim HW. Core-shell designed scaffolds for drug delivery and tissue625
engineering. Acta Biomater 2015; 21: 2-19.626
[13] Yu DG, Yang JH, Wang X, Tian F. Liposomes self-assembled from627
electrosprayinged composite microparticles. Nanotechnology 2012; 23:105606.628
[14] Liu ZP, Cui L, Yu DG, Zhao ZX, Chen L. Electrosprayed core-shell solid629
dispersions of acyclovir fabricated using an epoxy-coated concentric spray head. Int J630
Nanomed 2014;9:1967-1977.631
[15] Yu DG, Williams GR, Yang JH, Wang X, Yang JM, Li XY. Solid lipid632
nanoparticles self-assembled from electrosprayed polymer-based micoparticles. J633
Mater Chem 2011;21:15957-15961.634
27
[16] Sun J, Xianyu Y, Jiang X. Point-of-care biochemical assays using gold635
nanoparticle-implemented microfluidics. Chem Soc Rev 2014;43:6239-6253.636
[17] Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as637
a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm638
2013;85:427-443.639
[18] Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F,640
Langer R, Farokhzad OC. Self-assembled lipid--polymer hybrid nanoparticles: a641
robust drug delivery platform. ACS Nano 2008; 2:1696-1702.642
[19] Qin CC, Duan XP, Wang L, Zhang LH, Yu M, Dong RH, Yan X, He HW, Long643
YZ. Melt electrospinning of poly(lactic acid) and polycaprolactone microfibers by644
using a hand-operated wimshurst generator. Nanoscale 2015;7:16611-16615.645
[20] Jiang H, Wang L, Zhu K. Coaxial electrospinning for encapsulation and646
controlled release of fragile water-soluble bioactive agents. J Control Release647
2014;193: 296-303.648
[21] Erickson AE, Edmondson D, Chang FC, Wood D, Gong A, Levengood SL,649
Zhang M. High-throughput and high-yield fabrication of650
uniaxially-alignedchitosan-based nanofibers by centrifugal electrospinning.651
Carbohydr Polym 2015;134:467-474.652
[22] Jiang K, Long YZ, Chen ZJ, Liu SL, Huang YY, Jiang X, Huang ZQ.653
Airflow-directed in situ electrospinning of a medical glue of cyanoacrylate for rapid654
hemostasis in liver resection. Nanoscale 2014;6:7792-7798.655
[23] Sun B, Long YZ, Zhang HD, Li MM, Duvail JL, Jiang XY, Yin HL, Advances656
in three-dimensional nanofibrous macrostructures via electrospinning. Prog Polym Sci657
2014;39:862-890.658
[24] Lu W, Sun J, Jiang X. Recent advances in electrospinning technology and659
biomedical applications of electrospun fibers. J Mater Chem B 2014;2:2369-2380.660
[25] Wang SW, Chen W, He S, Zhao QL, Li XH, Sun JS, Jiang XY.661
Mesosilica-coated ultrafine fibers for highly efficient laccase encapsulation.662
Nanoscale 2014;6: 6468-6472.663
[26] Yu DG, White K, Chatterton NP, Li Y, Li L, Wang X. Structural lipid664
nanoparticles self-assembled from electrospun core-shell polymeric nanocomposites.665
RSC Adv 2015;5:9462-9466.666
[27] Nagy ZK, Balogh A, Démuth B, Pataki H, Vigh T, Szabó B, Molnár K, Schmidt667
BT, Horák P, Marosi G, Verreck G, Assche IV, Brewste ME. High speed668
electrospinning for scaled-up production of amorphous solid dispersion of669
itraconazole. Int J Pharm 2015;480:137-142.670
[28] Kim SE, Wang J, Jordan AM, Shanda L, Korley TJ, Baer E, Pokorski JK.671
Surface modification of melt extruded poly(ε-caprolactone) nanofibers: toward a new 672
28
scalable biomaterial scaffold. ACS Macro Letters 2014;3:585-589.673
[29] Balogh A, Cselkó R, Démuth B, Verreck G, Mensch J, Marosi G, Nagy ZK.674
Alternating current electrospinning for preparation of fibrous drug delivery systems.675
Int J Pharm 2015;495:75-80.676
[30] Qian W, Yu DG, Li Y, Liao YZ, Wang X, Wang L. Dual drug release electrospun677
core-shell nanofibers with tunable dose in the second phase. Int J Mol Sci678
2014;15:774-786.679
[31] Yu DG, Li XY, Wang X, Yang JH, Annie Bligh SW, Williams GR. Nanofibers680
fabricated using triaxial electrospinning as zero order drug delivery systems. ACS681
Appl Mater Interfaces 2015;7:18891-18897.682
[32] Chen H, Wang N, Di J, Zhao Y, Song Y, Jiang L. Nanowire-in-microtube683
structured core/shell fibers via multifluidic coaxial electrospinning. Langmuir 2010;684
26:11291-11296.685
[33] Yarin AL. Coaxial electrospinning and emulsion electrospinning of core–shell686
fibers. Polym Adv Technol 2011;22:310-317.687
[34] Yarin AL, Zussman E, Wendorff JH, Greiner A. Material encapsulation and688
transport in core–shell micro/nanofibers,polymer and carbon nanotubes and689
micro/nanochannels. J Mater Chem 2007;17:2585-2599.690
[35] Lee MW, An S, Lee C, Liou M, Yarin AL, Yoon SS. Hybrid self-healing matrix691
using core-shell nanofibers and capsuleless microdroplets. ACS Appl Mater Interfaces692
2014;6:10461-10468.693
[36] Wang X, Zhang WJ, Yu DG, Li XY, Yang H. Epoxy resin nanofibers prepared694
using electrospun core/sheath nanofibers as templates. Macromol Mater Eng695
2013;298:664-669.696
[37] Yu DG, Zhu LM, Branford-White C, Bligh SWA, White K. Coaxial697
electrospinning with organic solvent for controlling the self-assembled nanoparticle698
size. Chem Commun 2011;47:1216-1218.699
[38] Agarwal S, Greiner A, Wendorff JH. Functional materials by electrospinning of700
polymers. Prog Polym Sci 2013;38:963-991.701
[39] Zhang Z, Liu S, Xiong H, Jing X, Xie Z, Chen X, Huang Y. Electrospun702
PLA/MWCNTs composite nanofibers for combined chemo- and photothermal therapy.703
Acta Biomater 2015; 26:115-123.704
[40] Yu DG,Williams GR, Wang X, Liu XK, Li HL, Bligh SWA. Dual drug release705
nanocomposites prepared using a combination of electrospraying and electrospinning.706
RSC Adv 2013;3:4652-4658.707
[41] Su Y, Su Q, Liu W, Lim M, Venugopal JR, Mo X, Ramakrishna S, Al-Deyab SS,708
El-Newehy M. Controlled release of bone morphogenetic protein 2 and709
dexamethasone loaded in core-shell PLLACL-collagen fibers for use in bone tissue710
29
engineering. Acta Biomater 2012;8:763-771.711
[42] Yu DG, Branford-White C, Bligh SWA, White K, Chatterton NP, Zhu LM712
Improving polymer nanofiber quality using a modified co-axial electrospinning713
process. Macromol Rapid Commun 2011;32:744-750.714
[43] Yu DG, Chian W, Wang X, Li XY, Li Y, Liao YZ. Linear drug release membrane715
prepared by a modified coaxial electrospinning process. J Membrane Sci 2013, 428,716
150-156.717
[44] Jiang S, Duan G, Zussman E, Greiner A, Agarwal S. Highly flexible and tough718
concentric tri-axial polystyrene fibers. ACS Appl Mater Interfaces 2014;6:5918-5923.719
[45] Liu W, Ni C, Chase DB, Rabolt JF. Preparation of multilayer biodegradable720
nanofibers by tri-axial electrospinning. ACS Macro Lett 2013;2:466-468.721
[46] Labbaf S, Ghanbar H, Stride E, Edirisinghe M. Preparation of multilayered722
polymeric structures using a novel four-needle coaxial electrohydrodynamic device.723
Macromol Rapid Commun 2014;35:618-623.724
[47] Starr JD, Andrew JSA. Route to synthesize multifunctional tri-phase nanofibers.725
J Mater Chem C 2013;1:2529-2533.726
[48] Zhao Y, Cao X, Jiang L. Bio-mimic multichannel microtubes by a facile method.727
J Am Chem Soc 2007;129:764-765.728
[49] Han D, Steckl A. Triaxial electrospun nanofiber membranes for controlled dual729
release of functional molecules. ACS Appl Mater Interfaces 2013;5:8241-8245.730
[50] Illangakoon UE, Yu DG, Ahmad BS, Chatterton NP, Williams GR.731
5-fluorouracil loaded Eudragit fibers prepared by electrospinning. Int J Pharm732
2015;495:895-905.733
[51] Small DM. Phase equilibria and structure of dry and hydrated egg734
lecithin. J Lipid Res 1967;8:551-557.735
[52] O'brien WM. Adverse reactions to nonsteroidal anti-inflammatory drugs.736
Diclofenac compared with other nonsteroidal anti-inflammatory drugs. Am J Med737
1986;80(4B): 70-80.738
[53] Gibofsky A. Low-dose SoluMatrix diclofenac: a review of safety across two739
phase III studies in patients with acute and osteoarthritis pain. Expert Opin Drug Saf740
2015;25:1-13.741
[54] Kawabata Y, Wada K,Nakatani M, Yamada S, Onoue S. Formulation design for742
poorly water-soluble drugs based on biopharmaceutics classification system: basic743
approaches and practical applications. Int J Pharm 2011;420:1-10.744
[55] Ritschel WA, Koch HP, Alcorn GJ. In vivo-in vitro correlations with745
sustained-release theophylline preparations. Methods Find Exp Clin Pharmacol746
1984;6:609-618.747
30
[56]Kriwet K, Müller-Goymann CC, Diclofenac release from phospholipid drug748
systems and permeation through excised human stratum corneum. Int J Pharm 1995;749
125:231-242750
[57]Hamori M, Yoshimatsu S, Hukuchi Y, Shimizu Y, Fukushima K, Sugioka N,751
Nishimura A, Shibata N. Preparation and pharmaceutical evaluation of nano-fiber752
matrix supported drug delivery system using the solvent-based electrospinning753
method. Int J Pharm 2014; 464:243-251.754
[58]Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. Preparation and755
characterization of nanofibers containing amorphous drug dispersions generated by756
electrostatic spinning. Pharm Res 2003; 20:810-817.757
[59]Démuth B, Nagy ZK, Balogh A, Vigh T, Marosi G, Verreck G, Assche IV,758
Brewster ME. Downstream processing of polymer-based amorphous solid dispersions759
to generate tablet formulations. Int J Pharm 2015;486:268-286.760
[60] Dzenis Y. Spinning continuous fibers for nanotechnology. Science761
2004;304:1917-1919.762
[61] Chen CH, Chen SH, Shalumon KT, Chen JP. Dual functional core-sheath763
electrospun hyaluronic acid/polycaprolactone nanofibrous membranes embedded with764
silver nanoparticles for prevention of peritendinous adhesion. Acta Biomater 2015;765
26:225-235.766
767
768
769
Table and Figures Legend770
771
Table 1. Key details of the electrospinning processes and resultant fibers772
Fig. 1. A diagram of the modified tri-axial electrospinning process and its use for773
preparing core-shell drug-loaded nanofibers.774
Fig. 2. The implementation of modified tri-axial electrospinning: (a) the connection of775
the spinneret with the power supply and the working fluids (left), and images of the776
spinneret (insets); (b) a digital photograph of the tri-axial process (left), the droplet777
before a voltage of 15 kV was applied (top-right) and the compound Taylor cone778
(bottom-right).779
Fig. 3. FESEM images of the core-shell nanofibers and their size distributions; (a1780
and a2) F1; (b1 and b2) F2; (c1 and c2) F3; (d1 and d2) F4. The inset to (d1) shows a781
clump of PL-DS.782
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Fig. 4. (a) A FESEM image of the cross-sections of F2 and (b) a TEM image showing783
the same.784
Fig. 5. XRD patterns of the raw materials (PL, EL100 and DS) and F2.785
Fig. 6. ATR-FTIR spectra and the molecular formula of the fiber components.786
Fig. 7. In vitro dissolution of DS and D2 (a) and the proposed drug release787
mechanism (b).788
Fig. 8. (a) The transmittance of the dissolution medium measured at 500 nm as a789
function of time and (b) the sizes of the PL-DS particles measured by SDLC at the790
end of the dissolution experiment.791
Fig. 9. Ex vivo permeation profiles of the F2 fibers and pure DS (n=6). It should be792
noted that it is not possible in the permeation experiment to distinguish between drug793
in solution and in very small particles (< 220 nm) which could pass through the794
filtration membrane used. Thus, some portion of the DS which had permeated in the795
“free in water” experiment could in fact be in very small nanoparticles.796
Fig. 10. The feasibility of different tri-axial electrospinning processes.797
798
